sorafenib has been researched along with sulfapyridine in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (sulfapyridine) | Trials (sulfapyridine) | Recent Studies (post-2010) (sulfapyridine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 487 | 30 | 77 |
| Protein | Taxonomy | sorafenib (IC50) | sulfapyridine (IC50) |
|---|---|---|---|
| Carbonic anhydrase 1 | Homo sapiens (human) | 0.276 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.276 | |
| Carbonic anhydrase 6 | Homo sapiens (human) | 0.276 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Gazzar, MGM; El-Hazek, RMM; El-Sabbagh, WA; Fadel, NA; Zaher, NH | 1 |
1 other study(ies) available for sorafenib and sulfapyridine
| Article | Year |
|---|---|
Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact.
Topics: Animals; Carcinoma, Hepatocellular; Cardiotoxicity; Drug-Related Side Effects and Adverse Reactions; Liver Neoplasms; Mice; Myocytes, Cardiac; Sorafenib; Sulfapyridine; Vascular Endothelial Growth Factor Receptor-2 | 2023 |